Diabetes during pregnancy is related to enhanced fetal growth, which has been associated with increased breast cancer risk. Whether daughters of mothers with a diagnosis of diabetes have an increased risk of breast cancer is not known.
Methods
We performed a retrospective cohort study of daughters of mothers with diabetes by linkage of the Swedish Multigeneration, Cause-of-Death and Patient Register between 1952 and 2005. Breast cancer cases were ascertained by linkage with the Swedish Cancer Register between 1958 and 2005. Standardized incidence ratios (SIRs) of breast cancer were calculated assuming a Poisson distribution for the observed cases.
Results
We identified 291,360 daughters of mothers with a diagnosis of diabetes before or after birth between 1952 and 2005. Among the daughters, 7,956 cases of breast cancer were diagnosed between 1964 and 2005. The total time of follow-up was 12,173,821 person years. The expected number of breast cancer cases was 9,204, resulting in an SIR of 0.86 (95% CI, 0.85 to 0.88). The decrease in risk associated with maternal diabetes was stronger for premenopausal (< 55 years of age) than postmenopausal (≥ 55 years of age) breast cancer (SIR 0.83 and 0.91, respectively). Among daughters of mothers with diabetes, a history of breast cancer in the mother increased the risk of breast cancer in the daughter (SIR 1.43, 1.32 to 1.54).
Conclusions
Daughters of mothers with a lifetime history of diabetes were at a decreased risk of breast cancer. The strongest negative association was found among premenopausal breast cancer.
Introduction
In 1990, Trichopoulos suggested that breast cancer risk was influenced by the fetal environment, particularly variations in hormone concentrations [1]. Since then, numerous studies have assessed the association of birth weight as an integrative measure of prenatal nutrition and growth and development of breast cancer. A recent review by Michels and Xue [2] reports that the majority of studies show a positive association with an overall increased risk of 23% (95% confidence interval (CI) 13% to 34%) for high compared with low birth weight, and the association appears to be restricted to premenopausal breast cancer. While early hypotheses suspected intrauterine estrogen as a key player, IGF-1 and IGF-2 subsequently emerged as prime candidates. The diabetic environment is associated with increased levels of glucose and insulin, which lead to accelerated fetal growth and increased cell proliferation and subsequently a higher proportion of macrosomia (birth weight ≥ 4,500 g) and large-for-gestational-age infants [3]. Women with diabetes mellitus have a modest but statistically increased risk of postmenopausal breast cancer that has been related to altered concentrations of insulin, IGF, and/or endogenous sex hormones [4, 5]. Because of the strong link between overweight and obesity, diabetes during pregnancy, and increased fetal growth [6], we hypothesized that daughters of mothers with a lifetime history of diabetes were at an increased risk for development of breast cancer.
Materials and methods
Study population
The study base from which our study population was drawn is the total female Swedish population from 1932 and onwards. The unique national registration number (NRN), assigned at birth or immigration, allowed linkage to the following population-based nationwide registers: the Multigeneration Register, the Patient Register, the Cancer Register, the Register of Causes of Death, the Population Register, and the Register of Population Changes (Figure 1). The linkage provided information on all incident breast cancers in the cohort during the period 1958 to 2005, all deaths during 1952 to 2005, dates of emigration, and information about vital status for each individual through the end of the follow-up period (31 December 2005). We used the Multigeneration Register to identify women born 1932 and onwards and their mothers who were alive in 1947 (the year of the introduction of the NRN). The exposure of interest was maternal diabetes, with the index participant indicated by hospitalization for diabetes or with diabetes as a contributing cause of death. Mothers with diabetes were identified from the Patient Register and from the Cause of Death Register (defined according to the relevant International Classification of Disease (ICD) codes ICD-7: 260; ICD-8: 250; ICD-9: 250, 648W, 648A; and ICD-10: E10-E14, O24) between 1964 and 2006. Diagnosis of breast cancer for mothers and daughters between 1958 and 2005, including date of diagnosis was ascertained through the Cancer Register. Person-time of follow-up was calculated for each daughter from 1958 or birth until the diagnosis of breast cancer, death, emigration, or 31 December 2005 (end of follow-up), whichever occurred first.
Figure 1
Study design.
The study was approved by one of the Regional Ethical Review Boards in Stockholm, Sweden. The board did not require the women to provide informed consent.
Statistical Analysis
As the measure of association, we used standardized incidence ratios (SIRs) of breast cancer. SIRs were calculated by dividing the observed number of breast cancers with that expected, based on sex-, age-, and calendar period-specific incidence rates in the general population of Sweden. Confidence intervals of 95% (95% CI) were calculated assuming a Poisson distribution for the observed number of cases [7]. The data were analyzed with SAS software (SAS Institute Inc., Cary, NC, USA).
Results
Through linkage among the Multigeneration Register, the Patient Register and the Cause of Death Register, we identified 291,360 daughters of mothers with a diagnosis of diabetes mellitus or gestational diabetes before or after birth from 1932 onwards. Among the daughters there were 7,956 cases of breast cancer between 1958 and 2005. The total time of follow-up was 12,173,821 person years. The expected number of breast cancer cases was 9,204, with a total SIR of 0.86 (95% CI, 0.85 to 0.88). The SIRs for breast cancer by the mother's age at diagnosis of diabetes are listed in Table 1. The lowest SIR for breast cancer was observed among maternal age at diabetes diagnosis between 50 to 59 years of age. The decrease in risk associated with maternal diabetes was stronger for premenopausal (< 55 years of age) than postmenopausal (≥ 55 years of age) breast cancer (SIR 0.83 and 0.91, respectively) (Table 2). Among the mothers there were 14,099 cases of breast cancer. Among daughters of mothers with diabetes, a history of breast cancer in the mother increased the risk of breast cancer in the daughter (SIR 1.43, 1.32 to 1.54) (Table 3). SIR for breast cancer was lowest before 1980, for all calendar periods the SIR was significantly below 1.0 (Table 4).
Table 1
Observed and expected breast cancers among daughters by mother's age at diagnosis of diabetes
In this retrospective cohort study on close to 8,000 breast cancer cases we observed a significantly decreased risk of breast cancer among daughters of mothers with a lifetime history of diabetes. The strongest negative association was found for premenopausal breast cancer, with a 17% reduction in risk. Hence the findings from our study are in contradiction to our hypothesis of an elevated risk of breast cancer among daughters of mothers with diabetes.
Previous studies have found that increased fetal growth measured by birth weight and height is positively associated with breast cancer risk. In a meta-analysis including studies published between 1980 and 2007, Xue et al. report a small but significant 15% increased risk of breast cancer for increased birthweight and an almost 30% risk increase for high birth length [8]. The associations appeared to be stronger for premenopausal than postmenopausal breast cancer. There was no association between gestational age at birth and subsequent breast cancer risk [8].
We did not have information on gestational age and birth weight of the daughters in the study, and therefore we could not explore whether the inverse association between maternal diabetes and breast cancer risk among the daughters was influenced by these perinatal factors. Another limitation of the study is that we were not able to distinguish between type 1, type 2, and gestational diabetes among mothers. Type 2 diabetes is by far the most common diabetes type, and the underlying biologic mechanisms affecting maternal glucose metabolism are similar for all types of diabetes. We were able to identify diabetes in the mother starting in 1965. Hence, diagnosis of diabetes in the mothers could be after the birth of the daughters being followed for breast cancer. We do not know whether the mother had previously been diagnosed with diabetes, in particular, prior to her pregnancy with the daughter, or whether the hospitalization was related to newly diagnosed diabetes; it is possible that the mother developed diabetes after the index daughter was born. Since diabetes develops over a considerable time period, however, the mother is likely to have been affected by insulin resistance and hyperinsulinemia much earlier and thus also during her pregnancy with the daughter [9].
Fetal weight is strongly correlated with maternal weight in early pregnancy and weight gain during pregnancy [10]. Overweight and obese mothers are more likely to give birth to infants with a high birth weight as well as large-for-gestational-age (LGA) infants [10]. Overweight and obesity are also closely linked to gestational diabetes and type 2 diabetes later in life [6]. We postulated that diabetes would increase the risk of breast cancer among the offspring. Besides gestational and type 2 diabetes, overweight and obesity are also closely linked to development of preeclampsia [11], and the risk increases in a dose-dependent manner with increasing maternal body mass index (BMI) ([12]. Intrauterine exposure to preeclampsia has been associated with a decreased risk of breast cancer among the offspring [13, 14]. Preeclampsia is linked to placental dysfunction and, as a consequence, fetal growth restriction. The placenta is the primary source of pregnancy hormones, and placental impairment may serve as an indirect marker for placental function during pregnancy. In a study by Cohn et al., markers for placental dysfunction such as low placental weight, small diameter, and presence of infarctions reduced the rate of breast cancer of the mother not explained by preeclampsia or other known breast cancer risk factors [15]. Reduced levels of estrogen by a decreased synthesis of the smaller placenta as well as increased androgen levels due to the inverse relation between placental size and androgen level may explain the reduction in breast cancer risk among women with preeclampsia [15]. Among parous women, the risk of breast cancer increases by placental weight of the pregnancies, and the association is strongest for premenopausal breast cancer [16]. Unfortunately, neither data on birth weight or placental weight nor on preeclampsia were available for the population in the current study.
Previous studies suggest a modest increase in risk of breast cancer among women with type 2 diabetes and gestational diabetes [5]. In the present study we did not have information on diabetes among the daughters and consequently we could not study its possible influence on breast cancer. We observed that diabetes in the mother had a stronger inverse association with premenopausal than postmenopausal breast cancer. Overweight and obese women have a higher incidence of postmenopausal breast cancer, whereas an inverse association has been consistently observed between BMI and premenopausal breast cancer [17]. In a large prospective Nordic study by Weiderpass et al. [18], a decreased risk of breast cancer was observed among overweight and obese women. Similar findings have been reported in a US study based on the Nurses' Health Study II [19]. The biological rationale for this decreased risk among overweight and obese women has been attributed to an increased proportion of anovulatory menstrual cycles resulting in decreased estradiol and progesterone levels [20]. However, this mechanism was not supported in the above mentioned studies [18, 19]. Apart from reduced estrogen levels [21], an increased concentration of androgens and low levels of SHBG have been suggested as the biological rationale for the association between obesity and reduced breast cancer risk among premenopausal women. However, a study based on the European Prospective Investigation into Cancer and Nutrition (EPIC) reported increased risk of premenopausal breast cancer with high levels of testosterone and androstenedione [22].
Breast cancer incidence is higher in women with high socioeconomic status. In a recent UK study, the relative risk of breast cancer among the most deprived women was 16 percent lower than in the least deprived [23]. Affluent women are more likely to have their first child at a later age, have fewer children in their lifetime, and have an increased use of hormone replacement therapy (HRT), factors that have been associated with an increased risk of breast cancer. Deprived women are more likely not to attend breast cancer screening programs, which may delay cancer diagnosis [24]. However, we observed that the lowest risk of breast cancer was found prior to 1980, before the breast screening program became nationwide in Sweden. Women with low socioeconomic status have higher prevalence of overweight and obesity, which are strongly related to the development of type 2 diabetes [25]. Hence, our findings of a decreased risk of breast cancer among daughters of mothers with diabetes may also be due to confounding by socioeconomic status and for age at first birth, since we were not able to adjust for these characteristics.
By comparing breast cancer incidence in daughters of mothers with diabetes to the general population, we probably underestimate the true association because diabetes often goes undiagnosed for several years. The prevalence of diabetes in Sweden has not increased between 1986 and 1999, and would therefore not influence the results [26]. Only few cohorts worldwide allow the study of prenatal exposures and cancer risk in adult life. This is the most likely reason why the association between maternal diabetes and breast cancer has not been studied to date. The major strengths of the present study include population-based data with almost complete information on breast cancer diagnosis ascertainment and the register linkage preventing recall or reporting bias and selection bias. It is likely that we have captured the most severe cases of diabetes in the cohort; however, this may only strengthen the results, as any association will most likely be identified. Since our comparison is made with an expected number of breast cancer cases in an age-standardized population in Sweden, any misclassification due to diabetes not detected will not introduce any bias. To the best of our knowledge, no previous study has considered the possible association between maternal diabetes and subsequent breast cancer risk in the daughter. Further studies accounting for maternal as well as fetal weight, preeclampsia, and age at first birth are warranted to verify these novel findings.
Conclusions
In conclusion we found that daughters of mothers with a lifetime history of diabetes were at a decreased risk of breast cancer. The strongest negative association was found among premenopausal breast cancer.
Abbreviations
BMI:
body-mass index
CI:
confidence interval
EPIC:
European Prospective Investigation into Cancer and Nutrition
HRT:
hormone replacement therapy
ICD:
International Classification of Disease
IGF:
insulin-like growth factor
LGA:
large-for-gestational-age
NRN:
national registration number
SHBG:
sex hormone-binding globulin
SIR:
standardized incidence ratio.
Declarations
Acknowledgements
This research was supported by the U.S. Department of Defense, Breast Cancer Research Program (W81XWH-07-1-0557 to K.B.M.).
Authors’ Affiliations
(1)
Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska University Hospital and Institute, T2
(2)
Division of Obstetrics and Gynaecology, Department of Women's and Children's Health, Karolinska University Hospital and Institute, H2
(3)
Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School
(4)
Department of Epidemiology, Harvard School of Public Health
References
Trichopoulos D: Hypothesis: does breast cancer originate in utero?. Lancet. 1990, 335: 939-940. 10.1016/0140-6736(90)91000-Z.View ArticlePubMedGoogle Scholar
Michels KB, Xue F: Role of birthweight in the etiology of breast cancer. Int J Cancer. 2006, 119: 2007-2025. 10.1002/ijc.22004.View ArticlePubMedGoogle Scholar
Sacks DA: Etiology, detection, and management of fetal macrosomia in pregnancies complicated by diabetes mellitus. Clin Obstet Gynecol. 2007, 50: 980-989. 10.1097/GRF.0b013e31815a6242.View ArticlePubMedGoogle Scholar
Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 2003, 26: 1752-1758. 10.2337/diacare.26.6.1752.View ArticlePubMedGoogle Scholar
Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007, 86: s823-835.PubMedGoogle Scholar
Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, Valente O: Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obes Rev. 2009, 10: 194-203. 10.1111/j.1467-789X.2008.00541.x.View ArticlePubMedGoogle Scholar
Breslow NE, Day NE: Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987, 1-406.Google Scholar
Xue F, Michels KB: Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 2007, 8: 1088-1100. 10.1016/S1470-2045(07)70377-7.View ArticlePubMedGoogle Scholar
Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002, 25: 1862-1868. 10.2337/diacare.25.10.1862.View ArticlePubMedGoogle Scholar
Shand AW, Bell JC, McElduff A, Morris J, Roberts CL: Outcomes of pregnancies in women with pre-gestational diabetes mellitus and gestational diabetes mellitus; a population-based study in New South Wales, Australia, 1998-2002. Diabet Med. 2008, 25: 708-715. 10.1111/j.1464-5491.2008.02431.x.View ArticlePubMedGoogle Scholar
O'Brien TE, Ray JG, Chan WS: Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. 2003, 14: 368-374. 10.1097/00001648-200305000-00020.View ArticlePubMedGoogle Scholar
Ekbom A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ: Evidence of prenatal influences on breast cancer risk. Lancet. 1992, 340: 1015-1018. 10.1016/0140-6736(92)93019-J.View ArticlePubMedGoogle Scholar
Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D: Intrauterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst. 1997, 89: 71-76. 10.1093/jnci/89.1.71.View ArticlePubMedGoogle Scholar
Cohn BA, Cirillo PM, Christianson RE, Berg van den BJ, Siiteri PK: Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst. 2001, 93: 1133-1140. 10.1093/jnci/93.15.1133.View ArticlePubMedGoogle Scholar
Cnattingius S, Torrang A, Ekbom A, Granath F, Petersson G, Lambe M: Pregnancy characteristics and maternal risk of breast cancer. JAMA. 2005, 294: 2474-2480. 10.1001/jama.294.19.2474.View ArticlePubMedGoogle Scholar
Brandt van den PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, Marshall JR, Miller AB, Rohan T, Smith-Warner SA, Speizer FE, Willett WC, Wolk A, Hunter DJ: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000, 152: 514-527. 10.1093/aje/152.6.514.View ArticlePubMedGoogle Scholar
Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E, Adami HO: A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1121-1127.PubMedGoogle Scholar
Michels KB, Terry KL, Willett WC: Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006, 166: 2395-2402. 10.1001/archinte.166.21.2395.View ArticlePubMedGoogle Scholar
Key TJ, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988, 24: 29-43. 10.1016/0277-5379(88)90173-3.View ArticlePubMedGoogle Scholar
Potischman N, Swanson CA, Siiteri P, Hoover RN: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996, 88: 756-758. 10.1093/jnci/88.11.756.View ArticlePubMedGoogle Scholar
Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, et al: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005, 97: 755-765.View ArticlePubMedGoogle Scholar
Shack L, Jordan C, Thomson CS, Mak V, Moller H: Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer. 2008, 8: 271-10.1186/1471-2407-8-271.View ArticlePubMedPubMed CentralGoogle Scholar
Maheswaran R, Pearson T, Jordan H, Black D: Socioeconomic deprivation, travel distance, location of service, and uptake of breast cancer screening in North Derbyshire, UK. J Epidemiol Community Health. 2006, 60: 208-212. 10.1136/jech.200X.038398.View ArticlePubMedPubMed CentralGoogle Scholar
Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006, 444: 840-846. 10.1038/nature05482.View ArticlePubMedGoogle Scholar
Eliasson M, Lindahl B, Lundberg V, Stegmayr B: No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. Diabet Med. 2002, 19: 874-880. 10.1046/j.1464-5491.2002.00789.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
